| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Human Endogenous Metabolite
No specific pharmacological target; it is an endogenous polyamine metabolite and serves as a biomarker. Polyamines are involved in cell growth, proliferation, and differentiation. Diacetylspermidine is produced from spermidine by the action of acetyltransferases, and elevated levels are associated with tumor growth. |
|---|---|
| ln Vitro |
No direct in vitro activity. N1,N8-Diacetylspermidine is a biomarker for cancer, with elevated levels detected in the urine of patients with colorectal and urogenital malignancies. It may be used as a prognostic indicator after treatment and during follow-up examinations of cancer patients.
|
| ln Vivo |
No direct in vivo activity. In animal models of cancer, urinary levels of N1,N8-Diacetylspermidine may correlate with tumor burden and treatment response. It is used as a non-invasive biomarker to monitor disease progression and therapeutic efficacy.
|
| Enzyme Assay |
No specific enzyme binding protocols. For detection and quantification of N1,N8-Diacetylspermidine in biological samples, a standard LC-MS/MS protocol is used: (1) Prepare urine or plasma samples by protein precipitation with methanol. (2) Add internal standard (deuterated N1,N8-diacetylspermidine). (3) Inject onto a C18 reverse-phase column with mobile phase of 0.1% formic acid in water/acetonitrile. (4) Detect using multiple reaction monitoring (MRM) transitions specific for the compound.
|
| Cell Assay |
(1) Seed cancer cells (e.g., colorectal, prostate) in culture flasks. (2) Treat cells with chemotherapeutic agents or experimental compounds for 24-72 h. (3) Collect culture supernatant, and perform protein precipitation. (4) Quantify N1,N8-Diacetylspermidine in the supernatant by LC-MS/MS. (5) Correlate levels with cell proliferation (MTT assay) and apoptosis (Annexin V/PI staining).
|
| Animal Protocol |
(1) Use 6-8 week old male nude mice bearing subcutaneous tumor xenografts (e.g., HCT116 colorectal cancer, 200 mm3). (2) Administer chemotherapeutic agents (e.g., 5-FU, 20 mg/kg, IP, q3d × 4). (3) Collect urine samples at days 0, 3, 7, 14, 21 via metabolic cages. (4) Extract urine, quantify N1,N8-Diacetylspermidine by LC-MS/MS. (5) Correlate urinary levels with tumor volume measured by caliper. (6) Perform ROC analysis to determine biomarker sensitivity/specificity.
|
| ADME/Pharmacokinetics |
Standard formulation for biomarker studies: urine or plasma samples are collected and stored at -80degC until analysis. N1,N8-Diacetylspermidine is stable in urine at -80degC for at least 6 months. Extraction method: add 5 uL of internal standard (10 ug/mL in methanol) to 100 uL of sample, precipitate proteins with 300 uL methanol, centrifuge at 14,000 rpm for 10 min, and analyze supernatant by LC-MS/MS.
|
| Toxicity/Toxicokinetics |
The compound is non-toxic as it is an endogenous human metabolite. At therapeutic doses of chemotherapy, urinary levels of N1,N8-Diacetylspermidine may increase transiently due to tumor cell death. There is no MTD for this compound itself. In vitro, CCK-8 assays on HEK293 cells show no cytotoxicity at concentrations up to 500 uM. The compound is for research use only.
|
| References |
|
| Additional Infomation |
N1,N8-Diacetylspermidine hydrochloride is an endogenous polyamine found in human urine, with elevated levels serving as a prognostic indicator for cancer, particularly colorectal and urogenital malignancies. It is used as a non-invasive biomarker in oncology research for monitoring treatment response and detecting recurrence. It is not FDA-approved for clinical diagnosis and is strictly for laboratory research use.
|
| Molecular Formula |
C11H24CLN3O2
|
|---|---|
| Molecular Weight |
265.780161857605
|
| Exact Mass |
265.155
|
| CAS # |
178244-42-3
|
| Related CAS # |
N1,N8-Diacetylspermidine;82414-35-5
|
| PubChem CID |
389612
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
17
|
| Complexity |
207
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)NCCCCNCCCNC(=O)C.Cl
|
| InChi Key |
RWKXLCKGDFFGNU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H23N3O2.ClH/c1-10(15)13-8-4-3-6-12-7-5-9-14-11(2)16;/h12H,3-9H2,1-2H3,(H,13,15)(H,14,16);1H
|
| Chemical Name |
N-[4-(3-acetamidopropylamino)butyl]acetamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~83.33 mg/mL (~313.53 mM)
H2O :~50 mg/mL (~188.13 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 10 mg/mL (37.63 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7625 mL | 18.8126 mL | 37.6251 mL | |
| 5 mM | 0.7525 mL | 3.7625 mL | 7.5250 mL | |
| 10 mM | 0.3763 mL | 1.8813 mL | 3.7625 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
